## DIC 2022-1-1 Appendices

Effects of Azoximer Bromide (Polyoxidonium®) Administration in Patients Hospitalized with Coronavirus Disease (COVID-19): An Open-Label, Multi-Center Study

Sergey V. Efimov<sup>1</sup>, Natallia V. Matsiyeuskaya<sup>2</sup>, Olga V. Boytsova<sup>3</sup>, Luydmila Yu. Akhieva<sup>4</sup>, Elena V. Kuntsevich<sup>5</sup>, Anastasia A. Troshina<sup>6</sup>, Elena I. Kvasova<sup>7</sup>, Anton A. Tikhonov<sup>8</sup>, Nadezhda F. Khomyakova<sup>8</sup>, Francisco Harrison<sup>9</sup>, Jean-François Rossi<sup>10</sup>, Timothy C. Hardman<sup>11</sup>.


Supplementary file 1. Criteria to determine presence of pneumonia

Pneumonia was considered present at a visit if:

- 1. Positive signs were observed on an X-ray/CT scan.
- 2. No positive signs on the X-ray/CT scan were noted but the visit lay between positive scans obtained on other days.
- 3. The visit was after the last recorded positive X-ray/CT scan OR no X-ray/CT scans were done for the patient during the study.
  - a. One of the following must also have applied: respiratory support was used, blood saturation was below 96%, respiratory rate was above 20, dyspnoea was present, cough was present.

In all other cases, pneumonia was considered absent.

Supplementary file 2. Individual Ordinal Scale score values over time presented by sex, patient, and study day (Intent-to-Treat population [n=81])



Supplementary file 3. Individual National Early Warning Score values over time presented by sex, patient, and study day (Intent-to-Treat population [n=81])

